China Pharma Holdings (CPHI) Short term Debt (2010 - 2026)

China Pharma Holdings has reported Short term Debt for 17 years, with the latest figure at $1.9 million in Q1 2026.

• For the quarter ending Q1 2026, Short term Debt rose 67.24% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $1.9 million (up 67.24% YoY), and the FY2025 full-year result was $2.0 million, up 94.7% from the prior year.
• Short term Debt for Q1 2026 stood at $1.9 million, down from $2.0 million in the prior quarter.
• The five-year high for Short term Debt was $4.3 million in Q1 2022, with the low at $1.0 million in Q4 2024.
• Historically, Short term Debt has averaged $1.9 million across 5 years, with a median of $1.4 million in 2025.
• Annual changes were most pronounced in 2022 — Short term Debt jumped 112.48% — and 2023, when it tumbled 66.73%.
• China Pharma Holdings' Short term Debt stood at $2.4 million in 2022, then plunged by 53.55% to $1.1 million in 2023, then decreased by 10.43% to $1.0 million in 2024, then surged by 94.7% to $2.0 million in 2025, then declined by 2.45% to $1.9 million in 2026.
• The last three Short term Debt figures came in at $1.9 million (Q1 2026), $2.0 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.